Mechanistic Underpinnings of Preeclampsia

NCT ID: NCT06567899

Last Updated: 2025-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-07-25

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preeclampsia is a dreadful disease with significant morbidity and mortality. Despite decades of research, we still need a proper diagnostic test or therapeutic option to treat this disorder. The proposed study will determine the diagnostic value of PBMC-secreted sFlt1 and determine the molecular mechanisms involved in its secretion. The molecular mechanisms can be novel therapeutic targets to treat this disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-pregnant with previous normal pregnancy

Non pregnant females

No interventions assigned to this group

Non-pregnant with previous known preeclampsia

Women with known preeclampsia in previous pregnancy

No interventions assigned to this group

First Trimester Pregnant (First antenatal visit)

Women in first trimester

No interventions assigned to this group

Second Trimester Pregnant

Women in second trimester

No interventions assigned to this group

Third Trimester with known preeclampsia

Women in third trimester with diagnosis of preeclampsia

No interventions assigned to this group

Third Trimester with Normal Pregnancy

Women in third trimester with no complications.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Patients with any evidence of genetic or non-genetic malformations of the fetus will be excluded from the study.
* The study will be conducted on women who are non-smokers and do not consume alcohol or recreational drugs.
* The study will be conducted only on primigravida females to minimize phenotyping variability.
* The women with a known history of any chronic disorder, including but not limited to hypertension, diabetes, pulmonary, renal, cardiac, or cerebrovascular disorders, will be excluded from the studies.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Arizona

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ravi Goyal, MD, PhD

Role: CONTACT

520-626-5573

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY00004565

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prenatal Aspirin and Postpartum Vascular Function
NCT05653973 RECRUITING EARLY_PHASE1